Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Bernard Silver, MD, is a Staff Member in the Department of Hematological Oncology and Blood Disorders at the Cleveland Clinic’s main campus. His specialty interests include Coagulation disorders (bleeding and thrombosis), including hemophilia, von Willebrand's disease, clotting factor deficiencies or inhibitors, thrombophilia (excess clotting), lupus anticoagulant or antiphospholipid syndrome, thrombocytopenia (ITP, TTP), and hemolytic anemia.
Dr. Silver is also an Associate Editor of the Cleveland Clinic Journal of Medicine, Course Director for Hematology at Cleveland Clinic Lerner College of Medicine and Program Director of bone marrow biopsies for Taussig Cancer Institute.
Dr. Silver earned his medical degree from the University of Michigan Medical School in Ann Arbor, Mich. He completed an internship and residency at Northwestern University Evanston Hospital in Evanston, IL. He also completed a fellowship at University of Michigan Health System in Ann Arbor.
He is board certified by the American Board of Internal Medicine with additional certifications in Hematology and Oncology.
He has been an invited lecturer and presenter on various aspects of coagulation, such as hemophilia, von Willebrand's disease and factor inhibitors as well as antiphospholipid syndrome and thrombophilia, among many others. Dr. Silver has also published a number of articles in peer-reviewed journals on topics related to anemia and adult thrombotic thrombocytopenic purpura.
Coagulation disorders, including hemophilia, von willebrand's disease, clotting factor deficiencies or inhibitors, thrombophilia, lupus anticoagulant or antiphospholipid syndrome, thrombocytopenia (ITP,TTP), hemolytic anemia.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 2/4/2015, Dr. Silver has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.